FDA-approved CBD (Epidiolex) causes dose-dependent liver toxicity at therapeutic doses, with increased risk when combined with valproate, and current models are insufficient to fully predict CBD safety.
CBD users, epilepsy patients on CBD, pharmacologists, hepatologists
Dose-dependent liver toxicity at therapeutic doses
What the researchers found
CBD causes dose-dependent hepatocellular toxicity at therapeutic doses. Risk is increased with valproate co-administration through an unknown mechanism. CBD metabolism involves CYP3A4 and CYP2C19, creating significant drug interaction potential. Current pharmacokinetic models and in vitro liver models have limitations in predicting CBD safety.
Why it matters
CBD is increasingly popular as both an FDA-approved drug and consumer product, but its liver toxicity potential is underappreciated. The drug interaction with valproate is particularly concerning since many epilepsy patients take both medications.
The numbers in context
CBD is FDA-approved for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in children aged 1+. Dose-dependent hepatotoxicity observed at therapeutic doses. CYP3A4 and CYP2C19 are primary metabolic enzymes.
How the study worked
Narrative review of pharmacokinetic modeling approaches, in vitro liver models, and evidence on CBD-induced hepatotoxicity mechanisms, focusing on FDA-approved Epidiolex for pediatric epilepsy.
What this study cannot tell us
Review focused on FDA-approved Epidiolex doses, which are higher than most consumer products. Mechanisms of hepatotoxicity not fully understood. In vitro models may not predict in vivo toxicity accurately. Consumer CBD product quality and dosing are highly variable.
How to read the evidence
Comprehensive review of pharmacokinetic and toxicology evidence, but key mechanisms remain unknown.
When this study was published
2024 review of CBD pharmacokinetics and hepatotoxicity modeling
The bigger picture
The gap between CBD's image as a safe natural product and its documented liver toxicity at therapeutic doses highlights the need for public education. Consumer CBD products, while often lower-dose, may still pose risks for people with liver conditions or taking hepatotoxic medications.
Questions still open
- At what doses do consumer CBD products begin to pose liver risk? Can biomarkers predict which patients are susceptible to CBD hepatotoxicity? What is the mechanism of the CBD-valproate interaction?
Common questions
Can CBD damage the liver?
Does this apply to over-the-counter CBD products?
Read the original research
Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.
Drug metabolism and disposition: the biological fate of chemicals, 52(6), 508-515
Citation
Beers, Jessica L; Zhou, Zhu; Jackson, Klarissa D. (2024). Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.. Drug metabolism and disposition: the biological fate of chemicals, 52(6), 508-515. https://doi.org/10.1124/dmd.123.001435
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk